ReviewWorld journal of gastroenterology2022
Management of liver diseases: Current perspectives.
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Serum Insulin-Like Growth Factor 1 and the Prognosis of Patients With Advanced Liver Diseases: A Meta-Analysis.Clinical and translational gastroenterology · 2025Pooled it
- Socio-Occupational Aspects in Liver Transplant Candidates and Recipients: A Retrospective Cohort Study.Journal of occupational rehabilitation · 2026Article
- CRISPR and the Promise of Gene Editing: Unlocking Curative Possibilities for Liver Disorders Worldwide.ACG case reports journal · 2026Article
- Prospective Comparison of DWI-Derived Virtual MR Elastography and Conventional MR Elastography in Metabolic Dysfunction-Associated Steatotic Liver Disease and Healthy Volunteers.Journal of magnetic resonance imaging : JMRI · 2026Article
- Exercise attenuates high-fat diet-induced liver injury in mice via PPARα pathway and reduction of oxidative stress and inflammation.Journal of physiology and biochemistry · 2026Article
- Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases.Journal of gastroenterology and hepatology · 2026Review
- CD8 regulatory T cells are a novel type regulatory T cells in the induction of transplantation immune tolerance.Frontiers in immunology · 2026Article
- Hepatoprotective Effects of Fused Pyridine Derivatives: Regulation of the TGF-β/Smad, miR-21/Smad7, and PPARγ Pathways in Carbon Tetrachloride-Induced Liver Fibrosis.Drug design, development and therapy · 2026Article
- Sex dimorphism and substrate dependency of liver mitochondrial bioenergetics and HAmerican journal of physiology. Gastrointestinal and liver physiology · 2025Article
- Rare liver diseases - Etiology, diagnosis and management: A review.Biomolecules & biomedicine · 2025Review
- Green-Synthesized Silver Nanoparticles from Garlic Peel Target NF-κB and Redox Imbalance: A Novel Therapeutic Strategy Against Pyrogallol-Induced Hepatotoxicity in Rats.Nanomaterials (Basel, Switzerland) · 2025Article
- Dexamethasone-boosted mesenchymal stem cell secretome: insight into hepatic protection.BMC biotechnology · 2025Article
- Plant extracts with antioxidant and hepatoprotective benefits for liver health: A bibliometric analysis of drug delivery systems.World journal of gastroenterology · 2025Article
- Percutaneous thermal ablation in hepatocellular carcinoma patients with and without TIPS.Abdominal radiology (New York) · 2025Article
- Preventive and Therapeutic Effects of Baicalein, Galangin, and Isorhamnetin in Chronic Liver Diseases: A Narrative Review.Molecules (Basel, Switzerland) · 2025Review
- Current perspectives of viral hepatitis.World journal of gastroenterology · 2024Review
- Artificial Intelligence in Liver Diseases: Recent Advances.Advances in therapy · 2024Review
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- Hesperetin derivative 2a inhibits lipopolysaccharide-induced acute liver injury in mice via downregulation of circDcbld2.Acta pharmacologica Sinica · 2024Article
- Hepatoprotective Effect of a New FFAR1 Agonist-N-Alkylated Isobornylamine.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is increasing incidence and prevalence of acute and chronic liver diseases (CLDs) all over the world which influence the quality of life and can give rise to life threatening complications. The burden of advanced liver disease due to hepatitis B has been controlled by antivirals but its eradication is difficult soon. Highly effective directly acting antiviral therapy has reduced the burden of hepatitis C but is partially offset by increasing IV drug abuse. Non-alcoholic fatty liver disease pandemic is on and there is recent alarming increase in alcohol related liver disease, both of which have no drug cure apart from control of the risk factors. Genetic factors have been identified in progression of all forms of CLD. Due to better management of complications of CLD, the life span of patients have increased spiking the number of hepatocellular carcinoma (HCC) and patients needing liver transplantation (LT). The present severe acute respiratory syndrome coronavirus pandemic has affected the outcome CLD including LT in addition to causing acute hepatitis. Better diagnostics and therapeutics are available for liver fibrosis, portal hypertension, HCC and post LT management and many drugs are under trial. The present review summarises the current scenario of the epidemiology and the advances in diagnosis and treatment of liver diseases including their complications like portal hypertension, HCC and LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.